Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supervised Insulin Degludec in Adolescents with T1D
NCT03400501Phase 1Completed
- Sponsor
- Yale University
- Start
- Oct 2017
- Primary completion
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin degludec in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Yale University. Primary endpoint: beta hydroxybutyrate levels at 4 months. Started Oct 2017; status: completed.
02
Drugs
insulin degludec
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03400501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03400501.